Cathepsin S genotypes are associated with Apo-A1 and HDL-cholesterol in lean and obese French populations

Clinical Genetics

Volumn 74, Issue 2, 2008, Pages 155-163

  Spielmann, N ^a,b,c   Mutch, D M ^a,b,c   Rousseau, F ^d   Tores, F ^d   Hager, J ^d   Bertrais, S ^a   Basdevant, A ^a,b,e   Tounian, P ^a,b,f   Dubern, B ^a,b,f   Galan, P ^a   Clément, Karine ^a,b,c,e  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Parc Scientifique de Luminy   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Apolipoprotein A1; Association study; Cathepsin S; High density lipoprotein cholesterol; Metabolic risk factors; SNP

Indexed keywords

APOLIPOPROTEIN A1; CATHEPSIN S; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALLELE; AMINO ACID SEQUENCE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FRANCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; APOLIPOPROTEIN A-I; BODY WEIGHTS AND MEASURES; CATHEPSINS; CHOLESTEROL, HDL; FEMALE; FRANCE; GENETIC SCREENING; GENOTYPE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 47149095991     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.01043.x     Document Type: Article

References (24)

1. Lutgens SP, Cleutjens KB, Daemen MJ et al. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007: 21 (12): 3029-3041.
2. Sukhova GK, Shi GP, Simon DI et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998: 102 (3): 576-583.
3. Sukhova GK, Zhang Y, Pan JH et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003: 111 (6): 897-906.
4. Rodgers KJ, Watkins DJ, Miller AL et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006: 26 (4): 851-856.
5. Lindstedt L, Lee M, Oorni K, et al. Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun 2003: 312 (4): 1019-1024.
6. Brolin RE, Bradley LJ, Wilson AC et al. Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity. J Gastrointest Surg 2000: 4 (5): 464-469.
7. Gleysteen JJ, Barboriak JJ. Improvement in heart disease risk factors after gastric bypass. Arch Surg 1983: 118 (6): 681-684.
8. Williams DB, Hagedorn JC, Lawson EH et al. Gastric bypass reduces biochemical cardiac risk factors. Surg Obes Relat Dis 2007: 3 (1): 8-13.
9. Taleb S, Lacasa D, Bastard JP, et al. Cathepsin S, a novel biomarker of adiposity: Relevance to atherogenesis. FASEB J 2005: 19 (11): 1540-1542.
10. Taleb S, Clement K. Emerging role of cathepsin S in obesity and its associated diseases. Clin Chem Lab Med 2007: 45 (3): 328-332.
11. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005: 437 (7063): 1299-1320.
12. Hercberg S, Preziosi P, Galan P et al. "The SU.VI.MAX Study": a primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. SUpplementation on VItamines et Mineraux AntioXydants. Food Chem Toxicol 1999: 37 (9-10): 925-930.
13. Hercberg S, Galan P, Preziosi P et al. The SU.VI.MAX Study: A randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004: 164 (21): 2335-2342.
14. Tounian P, Aggoun Y, Dubern B et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: A prospective study. Lancet 2001: 358 (9291): 1400-1404.
15. Clement K, Lahlou N, Ruiz J et al. Association of poorly controlled diabetes with low serum leptin in morbid obesity. Int J Obes Relat Metab Disord 1997: 21 (7): 556-561.
16. de Bakker PI, Yelensky R, Pe'er I et al. Efficiency and power in genetic association studies. Nat Genet 2005: 37 (11): 1217-1223.
17. Dolley G, Bertrais S, Frochot V et al. Promoter adiponectin polymorphisms and waist/hip ratio variation in a prospective French adults study. Int J Obes 2007: 32 (4): 669-675.
18. Cao H, Hegele RA. Human cathepsin S gene (CTSS) promoter-25G/A polymorphism. J Hum Genet 2000: 45 (2): 94-95.
19. Ordovas JM. Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet Assoc 2006: 106 (7): 1074-1081.
20. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007: 18 (2): 157-163.
21. Thurmond RL, Sun S, Karlsson L et al. Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs 2005: 6 (5): 473-482.
22. Vasiljeva O, Reinheckel T, Peters C et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007: 13 (3): 385-401.
23. Taleb S, Cancello R, Poitou C et al. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab 2006: 91 (3): 1042-1047.
24. Liu J, Ma L, Yang J et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006: 186 (2): 411-419.